IBS-M

ModifyHealth Announces Positive Clinical Data for its Low FODMAP Meal Program in Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

Retrieved on: 
Monday, October 31, 2022
American College of Gastroenterology, CEO, Low-FODMAP diet, Bloating, IBS, Hepatology, Low, Division, Diet, Patient, Irritable bowel syndrome, FODMAP, Diarrhea, AGAF, Program, Degenerative disease, QOL, ACG, Kidney disease, IBS-D, Abdominal pain, University, Education, American College, Food, Medicine, FACP, Food and Nutrition Service, IBS-M, Founder CEO, GI, FACG, Quality of life, Diabetes, Constipation, Monash University, Medical device, Dietary supplement, Gastroenterology

ATLANTA, Oct. 31, 2022 /PRNewswire/ -- ModifyHealth™ a nationwide provider of virtual dietitian support and Monash University Certified gut-friendly, Low FODMAP, gluten-free and Mediterranean meals announced today new data related to the clinical impact of ModifyHealth's Low FODMAP meal delivery service and program that were presented in poster sessions at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which was recently held October 21 to 26, 2022 in Charlotte, North Carolina.

Key Points: 
  • The data presented supports the effectiveness of the Low FODMAP diet for all IBS subtypes, including IBS-D, IBS-M, & IBS-C.
  • "The data presented at ACG 2022 is further confirmation of the clinical efficacy of the Low FODMAP protocol.
  • We're excited it also confirms improved outcomes by making the protocol simple to follow with GI dietitian support and home-delivered Low FODMAP meals."
  • Along with home-delivered Low FODMAP, gluten-free, Mediterranean, plant based, and low sodium meals, ModifyHealth provides dietitian support, remote patient monitoring, and education to ensure sustained benefits.

Global Irritable Bowel Syndrome with Constipation Drugs Market Report to 2030 - Featuring Abbott Laboratories, AstraZeneca and Sanofi Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, September 9, 2022
Health, Pharmaceutical, IBS-C, AstraZeneca, Public health, Food, Diarrhea, Pain, Research, Awareness, Pain scale, Qualitative research, Exercise, Disease, Solution, GI, Irritable bowel syndrome, IBS-M, Bayer, Constipation, IBS-D, Prevalence, Degenerative disease, CAGR, IBS, Abbott Laboratories, Woman, Geography, Growth, Patient, Pharmaceutical industry, Fine chemical, Agriculture, Dietary supplement, Marketing, Gum arabic

In 2021, North America dominated the regional irritable bowel syndrome with constipation drugs market, due to increased intake of irrational medications and lack of exercise, thereby causing irritable bowel syndrome associated with constipation.

Key Points: 
  • In 2021, North America dominated the regional irritable bowel syndrome with constipation drugs market, due to increased intake of irrational medications and lack of exercise, thereby causing irritable bowel syndrome associated with constipation.
  • This report provides a detailed description of global irritable bowel syndrome with constipation drugs market segmenting market by drug types, prescription type, and geography.
  • This report aids the market stakeholders to make improved decisions and strategies in the irritable bowel syndrome with constipation drugs market.
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Irritable Bowel Syndrome with Constipation Drugs market worldwide?

metaMe Health partners with Indegene to launch Regulora®, an FDA-cleared Prescription Digital Therapeutic for adults with Irritable Bowel Syndrome

Retrieved on: 
Tuesday, March 22, 2022
Life, Health, Therapy, LinkedIn, PDT Standard, IBS-D, IBS, Partnership, Diarrhea, Adult, University of North Carolina at Greensboro, Aetna Health Inc. v. Davila, IOS, Irritable bowel syndrome, CEO, Pain, Quality of life, Artificial intelligence, Android, Disease, Degenerative disease, Twitter, IBS-C, Digital, GDH, Machine learning, GLOBE, MetaMed, Constipation, PDT, Hepatology, FDA, Division, University, Patient, Abdominal pain, IBS-M, Pharmaceutical industry, Health insurance, Medicine, Indegene, Gastroenterology

To help metaMe Health launch Regulora, Indegene brings deep healthcare expertise and advanced omnichannel capabilities powered by artificial intelligence and machine learning.

Key Points: 
  • To help metaMe Health launch Regulora, Indegene brings deep healthcare expertise and advanced omnichannel capabilities powered by artificial intelligence and machine learning.
  • Indegenes unique Co-Commercialization model ensures that Regulora reaches the right patients while allowing metaMe to focus on its mission of developing innovative Prescription Digital Therapeutics.
  • Tim Rudolphi, CEO at metaMe Health, says, We are excited to introduce Regulora as the first FDA-authorized treatment of its kind for IBS in adults.
  • Prescription Digital Therapeutics deliver evidence-based therapeutic interventions through high-quality software programs to prevent, manage, or treat a medical disorder or disease.

metaMe Health Raises $2.2 Million to Bring Its IBS Solution to Market

Retrieved on: 
Tuesday, March 15, 2022
Software, Alternative Medicine, General Health, Health, Mental Health, Technology, Other Technology, Other Health, Awareness, Twitter, Abdominal pain, Quality of life, Irritable bowel syndrome, IBS-M, Apple, Patient, Aetna Health Inc. v. Davila, Investment, FDA, Pain, Degenerative disease, GDH, IBS-D, IBS, Life, Brain, Digital, CEO, Diarrhea, Android, PDT, Hyde Park Angels, Constipation, HPA, MetaMed, Life expectancy, Gastrointestinal tract, LinkedIn, IBS-C, Pharmaceutical industry, Health insurance, Regulora, metaMe Health, Inc., IBS, REGULORA, METAME HEALTH, INC., IBS

The funds will be used to continue preparation for Reguloras market launch and to build out metaMes commercial infrastructure.

Key Points: 
  • The funds will be used to continue preparation for Reguloras market launch and to build out metaMes commercial infrastructure.
  • IBS, a chronic condition of the gastrointestinal tract, is the cause of between 2.4 and 3.5 million doctors office visits each year.
  • We are thrilled to have the support of HPA as we prepare for the launch of Regulora, said Tim Rudolphi, CEO of metaMe Health.
  • metaMe Health, Inc. (metaMe), is a U.S. company that develops Prescription Digital Therapeutics (PDT) for the treatment of common chronic conditions.

TRULANCE® (plecanatide tablets) for Irritable Bowel Syndrome with Constipation in Adults is now Available to Canadians to Help Meet Treatment Gap that leaves 70 Per cent of Patients Unsatisfied(1)

Retrieved on: 
Tuesday, February 8, 2022
Woman, Prevalence, Bausch Health, Abdominal pain, Corpus callosum, Division, Irritable bowel syndrome, Research, IBS-D, Company, Hepatology, Health Canada, Seriousness, BHC, Incidence, Person, Canadian Digestive Health Foundation, IBS-U, Dermatology, Digestion, Patient, Pharmacy, Constipation, NYSE, Population, BrainScope Company, Inc., Life, Plecanatide, TSX, IBS-M, University Health Network, Optimism, IBS, Diarrhea, Human, Bloating, IBS-C, Global health, Health insurance, Pharmaceutical industry, QC, Finance, Gastroenterology

TRULANCE is approved by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults,2 and is the first treatment brought to market in Canada by the gastrointestinal division of the Company.

Key Points: 
  • TRULANCE is approved by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults,2 and is the first treatment brought to market in Canada by the gastrointestinal division of the Company.
  • "We know doctors are seeking alternatives to improve care for those Canadians with the often-debilitating symptoms of IBS-C."
    TRULANCE provides a solution to the treatment gap currently experienced by patients suffering from IBS-C.
  • In a recent survey of IBS-C patients across Canada, almost three out of four (72 per cent) said not all their symptoms are under control.
  • "This works towards our vision to help empower all Canadians to manage their digestive health with confidence and optimism."

metaMe Health Receives FDA Clearance for Regulora®, the First FDA-authorized Treatment Specifically for Abdominal Pain Due to Irritable Bowel Syndrome (IBS)

Retrieved on: 
Tuesday, November 30, 2021
Patient, Digital therapeutics, IBS-D, Health, Gastrointestinal tract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IBS-M, Irritable bowel syndrome, CEO, Bloating, Brain, IBS-C, Diagnosis, Clinical trial, Headache, University, Apple, Systematic review, Disease, COVID-19, Pain, CQD, Hepatology, Abdominal pain, Physician, Aetna Health Inc. v. Davila, Communication, Diarrhea, Adult, University of North Carolina at Pembroke, PDT, Smartphone, Digital, Android, Constipation, FDA, Division, Therapy, Assistant, GDH, Life, Food, Fatigue, IBS, Quality of life, Dietary supplement, Pharmaceutical industry, Medical imaging

Treatment of abdominal pain associated with IBS is poised for a fundamental shift in clinical practice.

Key Points: 
  • Treatment of abdominal pain associated with IBS is poised for a fundamental shift in clinical practice.
  • "The FDA's clearance of Regulora, our first PDT, is a major achievement for the company," said Tim Rudolphi, CEO of metaMe Health.
  • Irritable Bowel Syndrome is a chronic condition of the lower gastrointestinal tract that affects 10-15% of adults in the United States.
  • PDTs are developed under rigorous conditions complete with clinical trials, FDA clearance, and availability only through a physician's prescription.